New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 23, 2014
09:52 EDTGWPHGW Pharmaceuticals rises for second day, levels to watch
Shares were on a tear yesterday to the upside and today the stock is trying higher once again. At the current price of $65.35, up 7.5% from yesterday's close, next resistance is at $66.83 and then the session high at $68.45. Support is at $63.94.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 14, 2015
08:38 EDTGWPHGW Pharmaceuticals price target raised to $120 from $102 at Leerink
Leerink analyst Paul Matteis raised his price target for shares of GW Pharmaceuticals to $120 after the American Academy of Neurology disclosed updated Epidiolex data from 137 patients. Matteis calls the data better than expectations saying they showed a "much greater" magnitude of overall seizure reduction than in the October update and a "consistent, robust effect" in larger samples of Dravet and Lennox Gastaut patients. He now assumes higher Epidiolex peak market penetrations and more use in the broader refractory pediatric epilepsy population. The analyst reiterates an Outperform rating on GW Pharmaceuticals. The stock closed yesterday at $96.18 and is trading up $7.87 to $104.05 in premarket trading.
07:25 EDTGWPHGW Pharmaceuticals undervalued based on Epidiolex potential, says Cowen
Subscribe for More Information
April 13, 2015
16:09 EDTGWPHGW Pharmaceuticals notes new Epidiolex data released by AAN
GW Pharmaceuticals noted that the American Academy of Neurology, or AAN, issued a press release today on GW's investigational medicine, Epidiolex. Data in the AAN release are from physician-led FDA authorized Epidiolex "expanded access" programs for children and young adults with treatment-resistant epilepsy that have exhausted available treatment options. The data provide treatment effect information on a total of 137 patients who have at least 12 weeks of Epidiolex exposure. Safety data is provided on 213 patients, representing these 137 patients plus additional patients still in their first 12 weeks of treatment. Additional data will be presented in a poster at the AAN Annual Meeting on 22 April at 6.15pm EDT, at which time GW will make an additional disclosure.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use